Sampford Advisors Inc’s Post

Recursion and Exscientia have entered into a definitive agreement to create a global technology-enabled drug discovery leader with comprehensive capabilities. This merger combines Recursion’s biology exploration and translational capabilities with Exscientia’s precision chemistry design and automated synthesis expertise. The goal is to utilize advanced life sciences and technology to deliver treatments more efficiently and at a lower cost compared to traditional methods. The combined business is well-capitalized, with approximately $850 million in cash and cash equivalents, and expects to achieve annual synergies exceeding $100 million. The partnership will also enhance their pipeline, with around 10 clinical readouts anticipated over the next 18 months and potential milestone payments of $200 million over the next two years. 🔸 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲: The implications for healthcare and pharmacy are noteworthy, as this merger aims to streamline the drug discovery and development process. By integrating high-throughput biology and advanced chemistry automation, the new entity seeks to improve the efficiency of developing high-quality medicines. This approach may reduce drug development timelines and costs, ultimately benefiting patients with quicker access to new therapies. The collaboration with leading biopharma companies, such as Roche-Genentech, Sanofi, Bayer, and Merck KGaA, highlights the potential for advancements in oncology, rare diseases, and infectious diseases, positioning the combined company as a significant player in the biotechnology industry. 🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐑𝐞𝐜𝐮𝐫𝐬𝐢𝐨𝐧 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/eTSEfuYv #DrugDiscovery #BiotechInnovation #HealthcareAdvancement 🌐 Swenson Pharmacy Advisors (SPA) 𝐖𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/gWFbVAjz

🎥 Exclusive Video Premiere! 🌟 New Milestones & Inspiring Video from Cytonics Corporation - Witness Our Evolution! Become a shareholder: invest.cytonics.com 🎬 A Video Says 10,000 Words With immense pride and excitement, we're thrilled to bring you an update that marks not just progress but a leap towards a future where osteoarthritis can be effectively managed and treated. Today, we unveil a series of pivotal milestones accompanied by a brand-new marketing video that encapsulates the essence of our mission, the depth of our commitment, and the potential of our groundbreaking work. 🎉 2024 Is Off With A Bang! We are only 3 months in, and before quarter end we will have accomplished these major milestones on our path towards human clinical trials: 📜 Regulatory Submission Completed: We've successfully navigated the complex regulatory landscape to submit the necessary documents, setting the stage for our next phase of trials. 🧪 Phase 1 Protocol Finalized: Our meticulous planning has culminated in the finalization of the Phase 1 study protocol for CYT-108, ensuring a focused and effective evaluation process. 🏥 Clinical Site Activation: With strategic site selections, we're now poised to commence patient recruitment, bringing us closer to the real-world impact of our research. 🧬 GMP Manufacturing and Delivery: Achieving a significant benchmark, the Good Manufacturing Practice (GMP) manufacturing of CYT-108 has been completed, and our preparations are now in place at the clinical trial sites . 🤝 Collaboration with Australian CRO: Partnering with Southern Star Research, a leading Contract Research Organization in Australia, we're ensuring that the Phase 1 study of CYT-108 is managed with the utmost precision and expertise. ❤️ We Cherish Our Investors!  Your unwavering support has been crucial to our journey thus far. As we embark on this new chapter, filled with promise and potential, we invite you to continue standing with us. As an investor, you are joining a family of passionate scientists and physicians, Hell bent on saving the lives of over 600M people worldwide. Stay tuned for more updates as we forge ahead with our mission to revolutionize the treatment of osteoarthritis. Together, we are not just witnessing history. We are making it. #biotechnology #drugdevelopment #arthritis #clinicaltrials #pharmaceutical #investing #crowdfunding

🎥 Exclusive Video Premiere! 🌟 New Milestones & Inspiring Video from Cytonics Corporation - Witness Our Evolution In Realtime! Become a shareholder: invest.cytonics.com 🎬 A Video Says 10,000 Words With immense pride and excitement, we're thrilled to bring you an update that marks not just progress but a leap towards a future where osteoarthritis can be effectively managed and treated. Today, we unveil a series of pivotal milestones accompanied by a brand-new marketing video that encapsulates the essence of our mission, the depth of our commitment, and the potential of our groundbreaking work. 🎉 2024 Is Off With A Bang! We are only 3 months in, and before quarter end we will have accomplished these major milestones on our path towards human clinical trials: 📜 Regulatory Submission Completed: We've successfully navigated the complex regulatory landscape to submit the necessary documents, setting the stage for our next phase of trials. 🧪 Phase 1 Protocol Finalized: Our meticulous planning has culminated in the finalization of the Phase 1 study protocol for CYT-108, ensuring a focused and effective evaluation process. 🏥 Clinical Site Activation: With strategic site selections, we're now poised to commence patient recruitment, bringing us closer to the real-world impact of our research. 🧬 GMP Manufacturing and Delivery: Achieving a significant benchmark, the Good Manufacturing Practice (GMP) manufacturing of CYT-108 has been completed, and our preparations are now in place at the clinical trial sites . 🤝 Collaboration with Australian CRO: Partnering with Southern Star Research, a leading Contract Research Organization in Australia, we're ensuring that the Phase 1 study of CYT-108 is managed with the utmost precision and expertise. ❤️ We Cherish Our Investors!  Your unwavering support has been crucial to our journey thus far. As we embark on this new chapter, filled with promise and potential, we invite you to continue standing with us. As an investor, you are joining a family of passionate scientists and physicians, Hell bent on saving the lives of over 600M people worldwide. Stay tuned for more updates as we forge ahead with our mission to revolutionize the treatment of osteoarthritis. Together, we are not just witnessing history. We are making it. #biotechnology #drugdevelopment #arthritis #clinicaltrials #pharmaceutical #investing #crowdfunding

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of March 2024 we identified the following current VC trends in Europe:   - Total Healthcare & Life Sciences funding reached EUR 1,962m - Biotech received 60% of the total investment volume (EUR 1,172m) with oncology being the leading indication (53%) - In March Tubulis GmbH (Germany) secures the highest transaction volume with EUR 128m, followed by Nouscom (Switzerland) with EUR 76m and Mission Therapeutics (United Kingdom) with EUR 51m  - M&G Investments (United Kingdom) is the most active investor (by deal volume), followed by Patient Square Capital (United States) and Rock Springs Capital (United States)   More here: https://lnkd.in/dappZ5WX

How has Swiss biotech been performing in 2023? 📈 In April the Swiss Biotech Report 2024 was released and its findings were very encouraging for Switzerland's biotech landscape. 2023 marked a 50% increase in capital investment compared to 2022 and reached $2.2 billion. The industry also achieved a revenue of $8 billion in Switzerland. 💸 With public and private companies raising significant funds and Swiss contributions to the cautious yet optimistic IPO market, the country remains a leader in the industry. 🏅 Find out more in the article! ⬇️ https://lnkd.in/devcxekD #swissbiotech #SwissBiotechReport #capitalinvestment #revenuegrowth #IPO #biotechindustry #innovation #healthcare #Switzerland #biotechnews #pharma NewBiologix | Noema Pharma | Alentis Therapeutics | Rejuveron Life Sciences AG | MoonLake Immunotherapeutics (NASDAQ: MLTX) | Lonza | Oculis | CRISPR Therapeutics | Vertex Pharmaceuticals | Novartis | Roche | Flatiron Health | University of Pennsylvania

The biotech industry is showing signs of recovery in 2024 after facing several challenges in recent years. 🔹Key factors include a nearly 50% increase in FDA approvals for novel drugs in 2023, signalling renewed dynamism in the sector. 🔹Additionally, an improving IPO market and robust M&A activity are driving optimism. 🔹Despite economic pressures, the sector’s innovation and strategic shifts suggest a promising year ahead. See more below: #Biotech #FDA #Innovation #Healthcare

In an industry frequently aiming for breakthroughs, only so many winners will emerge from the many shots on goal. And as the market embarks on a “fragile recovery,” investors are looking for less risky drug candidates and companies that have the strongest data. Hear how these pharma and biotech leaders make the call to pick pipeline winners. Gavin Samuels, CBO, CinRx Pharma Anthony Mancini, COO, Genmab Stacy Feld, regional head, West North America, Johnson & Johnson Innovation Bill Newell, CEO, Sutro Biopharma, Inc. David J. Mazzo, Ph.D., CEO, Lisata Therapeutics, Inc. Andy Seid, partner, Bioluminescence Ventures Robert Jacks, CEO, Sparrow Pharmaceuticals, Inc. #pharma #pipeline https://lnkd.in/evtrFYNE

In a recent interview with PharmaVoice, CEO Bill Newell provides insights into the critical evaluation of preclinical data and emphasizes the importance of an experienced and collaborative team. #PharmaVoice #pipeline #industryinsights #SutroBio $STRO

Great insights discussed here by Peter Benton the CEO - Worldwide Clinical Trials on the landscape on Biopharma funding which is a very topical area at the moment My favourite quote from the article is: "Given today' environment, biopharma companies don't need more constraints. They need CRO's who will be genuine, flexible partners" Over the years and multiple conferences/meetings I have attended this is definitely what drives a lot of frustrations when Biotech/Pharma companies don't get the partnerships they are looking for and ultimately leading to this partnerships breaking down. https://lnkd.in/e3a6JhZY

🎥 Exclusive Video Premiere! 🌟 New Milestones & Inspiring Video from Cytonics Corporation - Witness Our Evolution! Become a shareholder: invest.cytonics.com 🎬 A Video Says 10,000 Words With immense pride and excitement, we're thrilled to bring you an update that marks not just progress but a leap towards a future where osteoarthritis can be effectively managed and treated. Today, we unveil a series of pivotal milestones accompanied by a brand-new marketing video that encapsulates the essence of our mission, the depth of our commitment, and the potential of our groundbreaking work. 🎉 2024 Is Off With A Bang! We are only 3 months in, and before quarter end we will have accomplished these major milestones on our path towards human clinical trials: 📜 Regulatory Submission Completed: We've successfully navigated the complex regulatory landscape to submit the necessary documents, setting the stage for our next phase of trials. 🧪 Phase 1 Protocol Finalized: Our meticulous planning has culminated in the finalization of the Phase 1 study protocol for CYT-108, ensuring a focused and effective evaluation process. 🏥 Clinical Site Activation: With strategic site selections, we're now poised to commence patient recruitment, bringing us closer to the real-world impact of our research. 🧬 GMP Manufacturing and Delivery: Achieving a significant benchmark, the Good Manufacturing Practice (GMP) manufacturing of CYT-108 has been completed, and our preparations are now in place at the clinical trial sites . 🤝 Collaboration with Australian CRO: Partnering with Southern Star Research, a leading Contract Research Organization in Australia, we're ensuring that the Phase 1 study of CYT-108 is managed with the utmost precision and expertise. ❤️ We Cherish Our Investors!  Your unwavering support has been crucial to our journey thus far. As we embark on this new chapter, filled with promise and potential, we invite you to continue standing with us. As an investor, you are joining a family of passionate scientists and physicians, Hell bent on saving the lives of over 600M people worldwide. Stay tuned for more updates as we forge ahead with our mission to revolutionize the treatment of osteoarthritis. Together, we are not just witnessing history. We are making it. #biotechnology #drugdevelopment #arthritis #clinicaltrials #pharmaceutical #investing #crowdfunding